Current Challenges in the Diagnosis and Treatment of Lung Cancer


Date & Location
Friday, September 29, 2017 7:30 AM - 4:15 PM   Volney Richmond Auditorium, Seattle, WA

Specialties
Hospitalist, Internal Medicine, Oncology, Oncology - Lung Cancer, Pulmonology, Radiation Oncology, Radiology

Overview

This course will explore specific challenging issues in the diagnosis and treatment of lung cancer. The importance of appropriate lung cancer screening, staging and radiographic and invasive evaluation will be presented. Difficult therapeutic topics include the appropriate treatment of indolent cancers, radiation versus surgery for early stage disease, and the rapidly expanding role of targeted and immunotherapy. The importance of a multi-disciplinary evaluation — including the patient’s perspective — will be discussed. Finally, live diagnostic and surgical cases will be presented along with actual case reviews by a tumor board panel.

Teaching methods include lecture, question and answer with faculty, live case demonstration, case discussion, patient experience, and hands-on practice.

TARGET AUDIENCE: This course is designed for physicians, fellows and residents in pulmonology, oncology, radiology, internal medicine and hospital medicine. This course will also be of interest to physician assistants, nurse practitioners, and mid-level providers with an interest in lung cancer.

Objectives
At the conclusion of this activity, participants should be able to:
  1. Manage the challenges in setting up and maintaining a successful lung cancer screening program
  2. Discuss pragmatic approaches to address smoking cessation in a lung cancer screening program
  3. Apply the new Fleischner criteria and staging recommendations
  4. Discuss the potential of liquid biopsies and genetic analysis in the workup of the suspicious nodule
  5. Describe links between the histologic and radiologic features of various types of lung cancer and its mimics
  6. Summarize the benefits and risks of surgical and radiation therapy in early stage disease
  7. Review actionable molecular subtypes of advanced NSCLC
  8. Summarize recent data regarding use of PD-1/PD-L1 active agents
  9. Discuss value to patients of biomarker testing, targeted therapy and immunotherapy
  10. Cite the role of multi-disciplinary boards in patient care

Registration

Register online through Wednesday, September 27, 2017.

Tuition: $195.00



Accreditation



The Virginia Mason Medical Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Virginia Mason Medical Center designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certifi cation (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Parking: Parking is not included with registration. Virginia Mason's downtown parking facilities are limited and reserved for patients, therefore we offer this map of public lots with walking routes to the Lindeman Pavilion.

Public transportation: Metro Bus routes serving the First Hill neighborhood include 2, 10, 12, 60, 193, and 303. Please consult the Metro Trip Planner for route information and schedules.